Triple therapy is accepted as the treatment of choice for H. pylori eradication. In industrialized countries, a proton pump inhibitor plus clarithromycin and amoxicillin or nitroimidazole have shown the best results. Our aims were: 1. To study the eradication rate of the association of a proton pump inhibitor plus tinidazole and clarithromycin on H. pylori infection in our population. 2. To determine if previous treatments, gender, age, tobacco, alcohol use, and non-steroidal anti-inflammatory drugs (NSAIDs) change the response to therapy.
The identification of H. pylori in the gastric epithelium and its relationship with peptic disease 1 resulted in a remarkable change in the management of peptic ulcers. It is a worldwide consensus that eradication of the bacterium is the corner stone of peptic ulcer cure 2, 3 . The low rates of eradication observed in mono therapies and double therapies have encouraged the use of three antibiotics or two antibiotics and a proton pump inhibitor 4, 5, 6 Efficacy, the short period of treatment, low doses, few side effects, and low cost, make triple therapy with a proton pump inhibitor, macrolide, and nitroimidazole a very acceptable treatment for H. pylori eradication 7, 8, 9 . In Brazil, as well as in all developing countries, the risk of a therapeutic failure because of H. pylori strains that are resistant to metronidazole has to be considered 7 , because of its worldwide use. The aim of our study was to observe the eradication rate of H. pylori in a Brazilian peptic ulcer population under this treatment. The influence of previous treatments, gender, age, tobacco, alcohol, and NSAID use on therapy was evaluated. The Ethical and Scientific Committee of Hospital das Clinicas approved this protocol. Before inclusion, all participants signed a post-informed consent statement.
PATIENTS AND METHOD
Patients' data were obtained from standard questionnaires conducted at patients' inclusion in the study.
H. pylori infection was confirmed by histological examination (H&E and Giemsa methods) and rapid urease test (RUT) performed on biopsy material taken during upper endoscopy (2 samples of antrum and 2 samples of gastric body). H. pylori was considered eradicated when the RUT and histological examination performed 10 to 12 weeks after the end of the treatment were negative.
Clarithromycin 250 mg plus tinidazole 500 mg and a proton pump inhibitor (lansoprazole 30 mg or omeprazole 20 mg) were dispensed twice a day for a seven-day period. After treatment, compliance was assessed by pill consumption. Patients were asked about adverse effects. Patients were requested to stop all medications except antacids if needed for dyspeptic symptom relief or other medications for chronic use in concomitant diseases.
Statistical analysis was performed with software package SPSS v.3.0 (SPSS Inc., USA). The variables, gender, age, previous treatment, tobacco, alcohol, and NSAIDs were analyzed by the chi-square method. A p value < 0.05 was taken as being significant. A multiple logistic regression analysis was also performed; eradication was the dependent variable, and gender, age, previous treatment, tobacco, alcohol, and NSAIDs were the independent variables.
RESULTS
Two hundred patients were included in the study. There were 196 patients available for analysis "per protocol", most of them female with mean age = 44 (range = 16 to 80). The demographic data are shown in table 1.
Side effects were observed in 36 patients (18%), usually mild ones. One patient had to stop medication because of severe nausea and vomiting. Taste alterations, nausea, diarrhea, and dizziness were the most frequent side effects observed. One patient reported glossitis and vulvae pruritus.
Patients' adherence was high. All except 3 patients took more than 90% of the pills.
H. pylori was eradicated in 128 of 196 (65%) patients (Table 2) . Therapy efficacy depended on the previous treatment. For patients previously treated, eradication percentage was 53% (49/92), rising to 76% (79/104) for untreated patients, a statistically significant difference (p< 0.01). Eradication rate was different in males: 71% (53/75) when compared to females: 62% (75/121), without a statistical difference (p = 0.21). Eradication was not affected by the use of tobacco (61% x 67%), alcohol (63% x 72%), or NSAIDs (69% x 64%). The rate for patients over 44 years: 73% (62/85) was higher than for those under 44: 60% (66/111), with p value = 0.05 (Table 3) . 
DISCUSSION
The objective of H. pylori-dependent peptic ulcer treatment should be healing the ulcer and eradication of the bacteria. Many treatment schedules have been suggested to eradicate H. pylori 6, 10, 11 . Eradication success depends mainly on adherence to treatment and bacterial resistance to medications [12] [13] [14] [15] . There is no doubt that the ideal treatment must be effective at a low cost, besides being simple and free of side effects. It is a consensus in developed countries that an acceptable eradication rate is 90% or more 2, 9, 11, 16 . Triple therapy with a proton pump inhibitor was considered the treatment of choice to eradicate H. pylori 2, 3, [17] [18] [19] [20] [21] [22] [23] . Association of a proton pump inhibitor plus amoxicillin or nitroimidazole and clarithromycin results in an eradication rate higher than 90% 6, 8, 11, 17, 18, [20] [21] [22] . In populations where resistance to metronidazole is more than 30%, low effectiveness has been reported 13, 14 . In Brazil, H. pylori resistance to metronidazole is over 30% 7 , so it was not surprising that the 90% success rate in eradication was not reached by our population [24] [25] [26] [27] . In our study, the compliance to treatment was good; all except 3 patients took more than 90% of the pills. Although we do not have data on bacteria sensitivity, the 76% eradication rate observed in the first treated patients was probably due to tinidazole resistance. Similarly, a greater proportion of metronidazole-resistant strains present in patients underwent treatment for the second time, could explain the low 53% eradication rate observed. Moshkowitz 28 obtained similar data. These results reinforce that it is preferable that nitroimidazoles not be used in triple therapy schedules in Brazil. Macheda and Zaterka (unpublished results) and Chehter et al. 29 obtained 85% eradication in patients undergoing 7-day treatment with lansoprazole 30 mg plus amoxicillin 1.0 g and clarithromycin 0.5 g bid. They show that the use of amoxicillin instead of tinidazole increases the eradication rate, which is similar to the results observed in developed countries. Side effects were reported by 18% of our patients, usually mild ones, therefore not interfering with adherence to treatment. Only one patient with persistent nausea and vomiting resulted in withdrawal from treatment. As observed by other investigators, we expected to find a higher eradication rate in males, since women would theoretically have been exposed to treatment with nitroimidazoles 30, 31 more often, and consequently would show a higher resistance to tinidazole. However, the eradication rate was similar in males and females. It is possible that males and females are equally exposed to the previous use of nitroimidazole in Brazil 7 .
In a recent work 32 , smoking was a predictive factor of treatment failure, but our study failed to confirm this, in agreement with the Kadayifçi report 33 . Alcohol and NSAID use did not influence the outcome of eradication therapy.
There was a predominance of women in our study, which is a rule in all outpatient services in Brazil 34 . We cannot rule out an increase in female prevalence of peptic ulcer as partially responsible for the increased number of women in our study. An increased incidence of women with peptic ulcer disease has been reported in the USA since 1980 35, 36 . The better eradication rate of therapy for patients over 44 years old is difficult to explain. Similarly, Cutler and Schubert 27 and Labens 37 also observed this response in elderly patients. Nevertheless, Moayyedi 31 did not find any influence of age on eradication rate using a treatment schedule similar to ours. 
